Phathom Pharmaceuticals (PHAT) Aktievy
Phathom Pharmaceuticals, Inc. är ett biofarmaceutiskt företag som fokuserar på att utveckla och kommersialisera behandlingar för gastrointestinala sjukdomar i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 5/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 1/6 |
| Utdelningar | 0/6 |
PHAT Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Phathom Pharmaceuticals, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$8.37 |
| 52 veckors högsta | US$18.31 |
| 52 veckors lägsta | US$8.21 |
| Beta | 0.51 |
| 1 månads förändring | -1.65% |
| 3 månaders förändring | -19.29% |
| 1 års förändring | -30.60% |
| 3 års förändring | -37.86% |
| 5 års förändring | -74.96% |
| Förändring sedan börsintroduktionen | -65.98% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Sep 09
PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing
Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.Seeking Alpha • Sep 09
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking Alpha
Uppdatering av berättelse • Aug 15
PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline
Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.Recent updates
Uppdatering av berättelse • Sep 09
PHAT: Label Expansion Plans And 2026 Profitability Path Will Support Bullish Repricing
Analysts have reset the fair value estimate for Phathom Pharmaceuticals to $10, reflecting a lower price target that they link to reduced revenue growth and profit margin expectations, a slightly higher discount rate, and more cautious assumptions around Voquezna uptake in a highly genericized market. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious tone around Voquezna and the company’s execution against its growth plans.Seeking Alpha • Sep 09
Phathom Pharmaceuticals: Specialist Economics Strengthens The Bull Case
Summary Phathom Pharmaceuticals is executing a specialist-focused strategy, targeting gastroenterologists to drive VOQUEZNA adoption and move toward sustainable profitability. Second-quarter 2026 revenue grew 88% to $74.3M, SG&A fell, and management forecasts 2026 revenue of $310–$325M with an 80% gross margin, signaling operating leverage. PHAT’s commercial runway is supported by $182.5M in cash and improved operating cash flows, but revenue-interest financing remains a material risk. Key value drivers include continued growth in covered prescriptions, disciplined spending, and successful as-needed dosing development, with competition from tegoprazan looming. Read the full article on Seeking AlphaUppdatering av berättelse • Aug 15
PHAT: Expanded Reflux Indication Will Support Anticipated 2026 Profitability Timeline
Analysts have trimmed the fair value estimate for Phathom Pharmaceuticals from $23.70 to $21.50 as recent cuts to Street price targets, slightly higher discount assumptions, and more cautious revenue growth and margin forecasts feed into updated models. Analyst Commentary Recent Street research on Phathom Pharmaceuticals points to a more cautious stance on valuation, even as several analysts keep positive ratings on the stock.Uppdatering av berättelse • Jun 15
PHAT: Research Momentum And 2026 Profitability Outlook Will Support Bullish Repricing
Analysts have raised their price target on Phathom Pharmaceuticals to $13.62, reflecting updated assumptions for the discount rate, revenue growth, profit margin, and future P/E following recent research support. What's in the News Phathom highlighted extensive clinical and scientific research on vonoprazan, the active ingredient in VOQUEZNA, at Digestive Disease Week 2026 in Chicago.Uppdatering av berättelse • Jun 01
PHAT: Clinical Momentum Will Support Anticipated 2026 Profitability Timeline
Analysts have adjusted their price target on Phathom Pharmaceuticals to $23.70. This reflects updated views on the discount rate, long-term margin potential, and future P/E assumptions following recent research commentary.Uppdatering av berättelse • May 02
PHAT: Regulatory Exclusivity Outlook Will Support Anticipated 2026 Profitability Timeline
Narrative update on Phathom Pharmaceuticals The updated analyst price target for Phathom Pharmaceuticals has moved to $23.70, with analysts pointing to refreshed models that factor in revised revenue growth and profit margin assumptions, an adjusted future P/E, and recent research highlighting expectations around potential profitability timing, regulatory exclusivity and consumer marketing uncertainty. Analyst Commentary Recent Street research on Phathom Pharmaceuticals highlights a mix of optimism around the path to profitability and caution around long term exclusivity and commercial execution.Uppdatering av berättelse • Apr 15
PHAT: Regulatory Exclusivity Outlook Supports Path To 2026 Profitability
Phathom Pharmaceuticals' fair value estimate has shifted from $22.90 to $23.70 as analysts factor in higher long term profit margin assumptions, recent price target increases to $25 and $13, and updated views on regulatory exclusivity and potential generic competition after 2032. Analyst Commentary Recent Street research provides a mixed but useful view of how expectations are settling around Phathom Pharmaceuticals' execution and long term earnings power.Uppdatering av berättelse • Apr 01
PHAT: Profitability In 2026 Will Challenge Post 2032 Generic Overhang
Narrative Update The analyst price target for Phathom Pharmaceuticals is now aligned with a fair value estimate of about $13.62, with analysts pointing to updated models following Q4 results, refined assumptions around revenue growth, profit margins and future P/E, as well as recent target increases to $13 and $25 that reflect views on regulatory exclusivity and the path toward potential profitability in early Q3 2026. Analyst Commentary Recent Street research around Phathom Pharmaceuticals has centered on updated models following Q4 results, with analysts adjusting their targets to reflect revised assumptions on regulatory exclusivity, marketing execution and the timing of potential profitability.Uppdatering av berättelse • Mar 18
PHAT: Profitability In 2026 Will Test Post 2032 Generic Assumptions
Narrative Update on Phathom Pharmaceuticals Analysts have raised Phathom Pharmaceuticals' price target to a range that now reaches up to $25, up from prior targets as low as $12, citing updated models after the Q4 earnings beat, revised assumptions around regulatory exclusivity and generic entry after 2032, and expectations for the company to work toward profitability in early Q3 2026. Analyst Commentary Analysts reviewing Phathom Pharmaceuticals after its Q4 earnings beat have adjusted their models and price targets, but with differing levels of enthusiasm.Uppdatering av berättelse • Mar 04
PHAT: Profitability Expected In 2026 Could Reframe Long Term Generic Risk
Narrative Update on Phathom Pharmaceuticals The analyst price target underpinning our fair value view on Phathom Pharmaceuticals has shifted from $12 to $13. This reflects updated models that factor in the recent Q4 earnings beat, revised assumptions on regulatory exclusivity and potential generic entry after 2032, and expectations around the company's path toward potential profitability in early Q3 2026.Uppdatering av berättelse • Feb 18
PHAT: Follow On Equity Raise Will Support Path To 2026 Profitability
Analysts have kept their $22.90 price target for Phathom Pharmaceuticals broadly unchanged, citing only marginal adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E assumptions in their valuation work. What's in the News Phathom Pharmaceuticals completed a follow on equity offering totaling approximately US$130.0 million.Uppdatering av berättelse • Feb 04
PHAT: Equity Raise And 2026 Profitability Outlook Will Support Further Upside
Analysts have maintained their overall view on Phathom Pharmaceuticals, making only modest adjustments to assumptions such as revenue growth, profit margin, and future P/E. Taken together, these inputs support an unchanged fair value estimate of US$22.90 per share.Uppdatering av berättelse • Jan 20
PHAT: Equity Raise And 2025 Profitability Outlook Will Support Further Upside
Analysts have modestly adjusted their price assumptions for Phathom Pharmaceuticals, and the implied fair value remains at $22.90. Small changes to revenue growth, profit margin expectations, and future P/E assumptions have effectively offset one another.Analysartikel • Jan 08
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27%
Despite an already strong run, Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have been powering on, with a gain...Uppdatering av berättelse • Jan 06
PHAT: Late-Stage Gastrointestinal Trials And 2025 Guidance Will Drive Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at US$22.90. This reflects only minor adjustments in key model inputs, including the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any change in their overall view.Uppdatering av berättelse • Dec 16
PHAT: Late-Stage Gastrointestinal Pipeline Progress Will Drive Upside Momentum
Analysts have slightly trimmed their price target on Phathom Pharmaceuticals from approximately $23.13 to $22.90 per share, reflecting modestly higher long term growth and margin expectations, offset by a lower projected valuation multiple. What's in the News First patient dosed in the Phase 2 pHalcon EoE-201 trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with topline results expected in 2027 (company announcement) Additional analyses from the pivotal Phase 3 pHalcon NERD-301 trial of VOQUEZNA in Non Erosive Reflux Disease published in the American Journal of Gastroenterology, highlighting benefits for nighttime GERD symptoms (company announcement, medical journal) Full year 2025 revenue guidance updated to a range of 170 million dollars to 175 million dollars, indicating expectations for continued commercial ramp (company guidance) Sanjeev Narula appointed Chief Financial and Business Officer, bringing extensive large cap pharma and transaction experience from prior CFO roles at Intra Cellular Therapies, Viatris, and Pfizer divisions (company announcement) Valuation Changes Fair Value Estimate has edged down slightly from approximately $23.13 to $22.90 per share.Uppdatering av berättelse • Dec 01
PHAT: Clinical Pipeline Advances And Index Inclusion Will Support Upside Momentum
Analysts have maintained their price target for Phathom Pharmaceuticals at $23.13 per share, citing consistent revenue growth expectations and stable profit margin forecasts as the basis for leaving their projections unchanged. What's in the News First patient dosed in Phase 2 pHalcon-EoE-201 clinical trial of VOQUEZNA tablets for eosinophilic esophagitis in adults, with primary and secondary results expected in 2027 (Key Developments) Updated full-year 2025 revenue guidance to a range of $170 million to $175 million (Key Developments) New data from Phase 3 pHalcon-NERD-301 trial for VOQUEZNA published, showing improvements in nocturnal symptoms for Non-Erosive Reflux Disease and highlighting safety considerations (Key Developments) Appointment of Sanjeev Narula as Chief Financial and Business Officer, bringing extensive financial and strategic experience from leadership roles at Intra-Cellular Therapies, Viatris, and Pfizer (Key Developments) Added to S&P Pharmaceuticals Select Industry Index (Key Developments) Valuation Changes Consensus Analyst Price Target remains steady at $23.13 per share with no change from previous estimates.Uppdatering av berättelse • Nov 17
PHAT: Early Clinical Trial Progress Will Drive Shares Higher
Analysts have maintained their fair value price target for Phathom Pharmaceuticals at $23.13 per share. They cite only marginal adjustments to growth estimates and risk assumptions.Uppdatering av berättelse • Nov 01
PHAT: Rising Profit Margins Will Drive Stronger Shareholder Value Ahead
Analysts have raised their price target for Phathom Pharmaceuticals from $21.38 to $23.13. They cite an improved profit margin outlook, despite more conservative revenue growth projections.Uppdatering av berättelse • Sep 04
Gastroenterology Focus Will Unlock Enduring Market Potential
Analysts reaffirmed their price target for Phathom Pharmaceuticals at $21.38, citing 10-year market exclusivity for Voquezna, diminished generic risk, and robust launch metrics as drivers of renewed confidence and market opportunity. Analyst Commentary FDA granted 10-year market exclusivity for Voquezna tablets under GAIN, extending exclusivity to May 2032 with a likely pediatric extension through late 2032.Analysartikel • Jul 19
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shares have retraced a considerable 27% in the last month, reversing a...Analysartikel • Jun 02
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump
Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) shareholders are no doubt pleased to see that the share price has bounced...Ny berättelse • May 09
Focused VOQUEZNA Marketing And Cost Cuts Will Secure 2032 Exclusivity
Phathom focuses on VOQUEZNA's market potential in GERD treatment to drive substantial revenue while aiming for profitability through strategic cost management.Analysartikel • Apr 18
Why We're Not Concerned Yet About Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) 27% Share Price Plunge
Unfortunately for some shareholders, the Phathom Pharmaceuticals, Inc. ( NASDAQ:PHAT ) share price has dived 27% in the...Seeking Alpha • Dec 11
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable
Summary Phathom Pharmaceuticals, Inc.'s vonoprazan received multiple approvals, but the stock price showed erratic behavior, spiking post-Q2 earnings and plummeting post-Q3 earnings. Despite significant prescription growth and revenue increases, Q3 showed slower progress, raising concerns about the drug's market uptake and second-line approval status. High SG&A expenses and limited cash runway pose financial risks, alongside unclear reasons for stagnant sales despite label expansions. I exited my PHAT position in August and have no plans to reinvest due to these uncertainties and financial concerns. Read the full article on Seeking AlphaSeeking Alpha • Sep 03
Following Up On Phathom Pharmaceuticals
Summary Today, we're following up on Phathom Pharmaceuticals to see how the marketing rollout of its flagship product VOQUENZA is proceeding. This drug received FDA clearance late last year and is aiming to displace Proton Pump Inhibitors in its market. Management has succeeded in getting the compound covered in most commercial plans and believes VOQUENZA have at least $3 billion in peak sales potential. However, the company is still seeing a significant quarterly cash burn rate and already has a decent chunk of debt on its balance sheet. Read the full article on Seeking AlphaSeeking Alpha • Jun 26
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Summary Phathom Pharmaceuticals stock has significantly declined since 2021, despite securing FDA approval for Vonoprazan to treat H. pylori infection and GERD. The company faced delays in launching its products due to the presence of a cancer-causing agent in commercial batches, but eventually received full FDA approval. PHAT aims to target a substantial market opportunity with Vonoprazan, potentially leading to a share price rally and challenging a billion-dollar market cap valuation. The delays in launching Voquenza have been frustrating, but now the company is conducting a full launch and may secure a lucrative label expansion with an approval in non-erosive GERD next month. Read the full article on Seeking AlphaAktieägarnas avkastning
| PHAT | US Pharmaceuticals | US Marknad | |
|---|---|---|---|
| 7D | -7.5% | -4.0% | -2.2% |
| 1Y | -30.6% | 43.7% | 13.1% |
Avkastning vs industri: PHAT presterade sämre än US Pharmaceuticals branschen som gav 43.7 % under det senaste året.
Avkastning vs Marknaden: PHAT presterade sämre än US marknaden som gav 13.1 % under det senaste året.
Prisvolatilitet
| PHAT volatility | |
|---|---|
| PHAT Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stabil aktiekurs: PHAT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PHAT s veckovolatilitet ( 10% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2018 | 371 | Steve Basta | www.phathompharma.com |
Phathom Pharmaceuticals, Inc. är ett biofarmaceutiskt företag som fokuserar på att utveckla och kommersialisera behandlingar för gastrointestinala sjukdomar i USA. Företaget utvecklar VOQUEZNA, som har slutfört kliniska fas III-studier för behandling av erosiv gastroesofageal refluxsjukdom (GERD) och relaterad halsbränna hos vuxna; och VOQUEZNA Triple Pak och VOQUEZNA Dual Pak som har slutfört kliniska fas III-studier för behandling av Helicobacter pylori, samt VOQUEZNA och vonoprazan för behandling av halsbränna i samband med icke-erosiv GERD och eosinofil esofagit hos vuxna och ungdomar. Bolaget bildades 2018 och har sitt huvudkontor i Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. Sammanfattning av grunderna
| PHAT grundläggande statistik | |
|---|---|
| Börsvärde | US$688.66m |
| Vinst(TTM) | -US$99.07m |
| Intäkter(TTM) | US$239.66m |
2.8x
P/S-förhållande-6.7x
P/E-förhållandeÄr PHAT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PHAT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$239.66m |
| Kostnad för intäkter | US$40.93m |
| Bruttovinst | US$198.73m |
| Övriga kostnader | US$297.81m |
| Intäkter | -US$99.07m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -1.25 |
| Bruttomarginal | 82.92% |
| Nettovinstmarginal | -41.34% |
| Skuld/egenkapitalförhållande | -159.6% |
Hur har PHAT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/10 14:25 |
| Aktiekurs vid dagens slut | 2026/09/10 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Phathom Pharmaceuticals, Inc. bevakas av 16 analytiker. 10 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Jenna Davidner | Barclays |
| null null | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |